Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus to treat multiple sclerosis. Polpharma Biologics will retain full responsibility for developing and manufacturing the biosimilar candidate. Teva will take charge of regulatory submissions and, subject to approval, subsequent commercialisation in the specified territories. Credit: JHVEPhoto / Shutterstock.com. Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS). Under the deal, Teva will hold exclusive rights to commercialise both intravenous and subcutaneous formulations of the biosimilar once it…

Source: Pharmaceutical Technology